CStone signs exclusive license agreement with Istituto Gentili for sugemalimab ...
Under the terms of the agreement, Gentili will receive exclusive commercialization rights for sugemalimab in 23 European countries, as well as the United Kingdom, Andorra, Monaco, San Marino, and Vatican City.


